Document:

EXHIBIT 10.5

                    AMENDED AND RESTATED SUBSIDIARY GUARANTEE

      AMENDED AND RESTATED SUBSIDIARY GUARANTEE, dated as of May 19, 2006 (this
"Guarantee"), made by each of the signatories hereto (together with any other
entity that may become a party hereto as provided herein, (the "Guarantors"), in
favor of the purchasers signatory (the "Purchasers") to that certain Amended and
Restated Securities Purchase Agreement, dated as of the date hereof, between
PracticeXpert, Inc., a Nevada corporation (the "Company"), and the Purchasers.

                                   WITNESSETH:

      WHEREAS, pursuant to that certain Amended and Restated Securities Purchase
Agreement, dated as of the date hereof, by and between the Company and the
Purchasers (the "Purchase Agreement"), the Company has agreed to sell and issue
to the Purchasers, and the Purchasers have agreed to purchase from the Company
the Company's 12% Secured Convertible Debentures, due May 19, 2007 (the
"Debentures"), subject to the terms and conditions set forth therein; and

      WHEREAS, each Guarantor will directly benefit from the extension of credit
to the Company represented by the issuance of the Debentures; and

      NOW, THEREFORE, in consideration of the premises and to induce the
Purchasers to enter into the Purchase Agreement and to carry out the
transactions contemplated thereby, each Guarantor hereby agrees with the
Purchasers as follows:

      1. Definitions. Unless otherwise defined herein, terms defined in the
Purchase Agreement and used herein shall have the meanings given to them in the
Purchase Agreement. The words "hereof," "herein," "hereto" and "hereunder" and
words of similar import when used in this Guarantee shall refer to this
Guarantee as a whole and not to any particular provision of this Guarantee, and
Section and Schedule references are to this Guarantee unless otherwise
specified. The meanings given to terms defined herein shall be equally
applicable to both the singular and plural forms of such terms. The following
terms shall have the following meanings:

            "Guarantee" means this Subsidiary Guarantee, as the same may be
      amended, supplemented or otherwise modified from time to time.

            "Obligations" means the collective reference to all obligations and
      undertakings of the Company of whatever nature, monetary or otherwise,
      under the Debentures, the Purchase Agreement, the Security Agreement, the
      Warrants, or any other future agreement or obligations undertaken by the
      Company to the Purchasers, together with all reasonable attorneys' fees,
      disbursements and all other costs and expenses of collection incurred by
      Purchasers in enforcing any of such Obligations and/or this Guarantee.

<PAGE>

      2. Guarantee. Each Guarantor hereby agrees as follows:

            (a) Guarantee.

                  (i) The Guarantors hereby, jointly and severally,
                  unconditionally and irrevocably, guarantee to the Purchasers
                  and their respective successors, endorsees, transferees and
                  assigns, the prompt and complete payment and performance by
                  the Company when due (whether at the stated maturity, by
                  acceleration or otherwise) of the Obligations.

                  (ii) Anything herein or in any other Transaction Document to
                  the contrary notwithstanding, the maximum liability of each
                  Guarantor hereunder and under the other Transaction Documents
                  shall in no event exceed the amount which can be guaranteed by
                  such Guarantor under applicable federal and state laws,
                  including laws relating to the insolvency of debtors,
                  fraudulent conveyance or transfer or laws affecting the rights
                  of creditors generally (after giving effect to the right of
                  contribution established in Section 2(b)).

                  (iii) Each Guarantor agrees that the Obligations may at any
                  time and from time to time exceed the amount of the liability
                  of such Guarantor hereunder without impairing the guarantee
                  contained in this Section 2 or affecting the rights and
                  remedies of the Purchasers hereunder.

                  (iv) The guarantee contained in this Section 2 shall remain in
                  full force and effect until all the Obligations and the
                  obligations of each Guarantor under the guarantee contained in
                  this Section 2 shall have been satisfied by payment in full.

                  (v) No payment made by the Company, any of the Guarantors, any
                  other guarantor or any other Person or received or collected
                  by the Purchasers from the Company, any of the Guarantors, any
                  other guarantor or any other Person by virtue of any action or
                  proceeding or any set-off or appropriation or application at
                  any time or from time to time in reduction of or in payment of
                  the Obligations shall be deemed to modify, reduce, release or
                  otherwise affect the liability of any Guarantor hereunder
                  which shall, notwithstanding any such payment (other than any
                  payment made by such Guarantor in respect of the Obligations
                  or any payment received or collected from such Guarantor in
                  respect of the Obligations), remain liable for the Obligations
                  up to the maximum liability of such Guarantor hereunder until
                  the Obligations are paid in full.

                  (vi) Notwithstanding anything to the contrary in this
                  Agreement, with respect to any defaulted non-monetary
                  Obligations the specific performance of which by the
                  Guarantors is not reasonably possible (e.g. the issuance of
                  the Company's Common Stock), the Guarantors shall only be
                  liable for making the Purchasers whole on a monetary basis for
                  the Company's failure to perform such Obligations in
                  accordance with the Transaction Documents.

                                       2
<PAGE>

            (b) Right of Contribution. Each Guarantor hereby agrees that to the
extent that a Guarantor shall have paid more than its proportionate share of any
payment made hereunder, such Guarantor shall be entitled to seek and receive
contribution from and against any other Guarantor hereunder which has not paid
its proportionate share of such payment. Each Guarantor's right of contribution
shall be subject to the terms and conditions of Section 2(c). The provisions of
this Section 2(b) shall in no respect limit the obligations and liabilities of
any Guarantor to the Purchasers, and each Guarantor shall remain liable to the
Purchasers for the full amount guaranteed by such Guarantor hereunder.

            (c) No Subrogation. Notwithstanding any payment made by any
Guarantor hereunder or any set-off or application of funds of any Guarantor by
the Purchasers, no Guarantor shall be entitled to be subrogated to any of the
rights of the Purchasers against the Company or any other Guarantor or any
collateral security or guarantee or right of offset held by the Purchasers for
the payment of the Obligations, nor shall any Guarantor seek or be entitled to
seek any contribution or reimbursement from the Company or any other Guarantor
in respect of payments made by such Guarantor hereunder, until all amounts owing
to the Purchasers by the Company on account of the Obligations are paid in full.
If any amount shall be paid to any Guarantor on account of such subrogation
rights at any time when all of the Obligations shall not have been paid in full,
such amount shall be held by such Guarantor in trust for the Purchasers,
segregated from other funds of such Guarantor, and shall, forthwith upon receipt
by such Guarantor, be turned over to the Purchasers in the exact form received
by such Guarantor (duly indorsed by such Guarantor to the Purchasers, if
required), to be applied against the Obligations, whether matured or unmatured,
in such order as the Purchasers may determine.

            (d) Amendments, Etc. With Respect to the Obligations. Each Guarantor
shall remain obligated hereunder notwithstanding that, without any reservation
of rights against any Guarantor and without notice to or further assent by any
Guarantor, any demand for payment of any of the Obligations made by the
Purchasers may be rescinded by the Purchasers and any of the Obligations
continued, and the Obligations, or the liability of any other Person upon or for
any part thereof, or any collateral security or guarantee therefor or right of
offset with respect thereto, may, from time to time, in whole or in part, be
renewed, extended, amended, modified, accelerated, compromised, waived,
surrendered or released by the Purchasers, and the Purchase Agreement and the
other Transaction Documents and any other documents executed and delivered in
connection therewith may be amended, modified, supplemented or terminated, in
whole or in part, as the Purchasers may deem advisable from time to time, and
any collateral security, guarantee or right of offset at any time held by the
Purchasers for the payment of the Obligations may be sold, exchanged, waived,
surrendered or released. The Purchasers shall have no obligation to protect,
secure, perfect or insure any Lien at any time held by them as security for the
Obligations or for the guarantee contained in this Section 2 or any property
subject thereto.

                                       3
<PAGE>

            (e) Guarantee Absolute and Unconditional. Each Guarantor waives any
and all notice of the creation, renewal, extension or accrual of any of the
Obligations and notice of or proof of reliance by the Purchasers upon the
guarantee contained in this Section 2 or acceptance of the guarantee contained
in this Section 2; the Obligations, and any of them, shall conclusively be
deemed to have been created, contracted or incurred, or renewed, extended,
amended or waived, in reliance upon the guarantee contained in this Section 2;
and all dealings between the Company and any of the Guarantors, on the one hand,
and the Purchasers, on the other hand, likewise shall be conclusively presumed
to have been had or consummated in reliance upon the guarantee contained in this
Section 2. Each Guarantor waives to the extent permitted by law diligence,
presentment, protest, demand for payment and notice of default or nonpayment to
or upon the Company or any of the Guarantors with respect to the Obligations.
Each Guarantor understands and agrees that the guarantee contained in this
Section 2 shall be construed as a continuing, absolute and unconditional
guarantee of payment without regard to (a) the validity or enforceability of the
Purchase Agreement or any other Transaction Document, any of the Obligations or
any other collateral security therefor or guarantee or right of offset with
respect thereto at any time or from time to time held by the Purchasers, (b) any
defense, set-off or counterclaim (other than a defense of payment or performance
or fraud or misconduct by Purchasers) which may at any time be available to or
be asserted by the Company or any other Person against the Purchasers, or (c)
any other circumstance whatsoever (with or without notice to or knowledge of the
Company or such Guarantor) which constitutes, or might be construed to
constitute, an equitable or legal discharge of the Company for the Obligations,
or of such Guarantor under the guarantee contained in this Section 2, in
bankruptcy or in any other instance. When making any demand hereunder or
otherwise pursuing its rights and remedies hereunder against any Guarantor, the
Purchasers may, but shall be under no obligation to, make a similar demand on or
otherwise pursue such rights and remedies as they may have against the Company,
any other Guarantor or any other Person or against any collateral security or
guarantee for the Obligations or any right of offset with respect thereto, and
any failure by the Purchasers to make any such demand, to pursue such other
rights or remedies or to collect any payments from the Company, any other
Guarantor or any other Person or to realize upon any such collateral security or
guarantee or to exercise any such right of offset, or any release of the
Company, any other Guarantor or any other Person or any such collateral
security, guarantee or right of offset, shall not relieve any Guarantor of any
obligation or liability hereunder, and shall not impair or affect the rights and
remedies, whether express, implied or available as a matter of law, of the
Purchasers against any Guarantor. For the purposes hereof, "demand" shall
include the commencement and continuance of any legal proceedings.

            (f) Reinstatement. The guarantee contained in this Section 2 shall
continue to be effective, or be reinstated, as the case may be, if at any time
payment, or any part thereof, of any of the Obligations is rescinded or must
otherwise be restored or returned by the Purchasers upon the insolvency,
bankruptcy, dissolution, liquidation or reorganization of the Company or any
Guarantor, or upon or as a result of the appointment of a receiver, intervenor
or conservator of, or trustee or similar officer for, the Company or any
Guarantor or any substantial part of its property, or otherwise, all as though
such payments had not been made.

            (g) Payments. Each Guarantor hereby guarantees that payments
hereunder will be paid to the Purchasers without set-off or counterclaim in U.S.
dollars at the address set forth or referred to in the Purchase Agreement.

      3. Representations and Warranties. Each Guarantor hereby makes the
following representations and warranties to Purchasers as of the date hereof:

                                       4
<PAGE>

            (a) Organization and Qualification. The Guarantor is a corporation,
duly incorporated, validly existing and in good standing under the laws of the
applicable jurisdiction set forth on Schedule 1, with the requisite corporate
power and authority to own and use its properties and assets and to carry on its
business as currently conducted. The Guarantor has no subsidiaries other than
those identified as such on the Disclosure Schedules to the Purchase Agreement.
The Guarantor is duly qualified to do business and is in good standing as a
foreign corporation in each jurisdiction in which the nature of the business
conducted or property owned by it makes such qualification necessary, except
where the failure to be so qualified or in good standing, as the case may be,
could not, individually or in the aggregate, (x) adversely affect the legality,
validity or enforceability of any of this Guaranty in any material respect, (y)
have a material adverse effect on the results of operations, assets, prospects,
or financial condition of the Guarantor or (z) adversely impair in any material
respect the Guarantor's ability to perform fully on a timely basis its
obligations under this Guaranty (a "Material Adverse Effect").

            (b) Authorization; Enforcement. The Guarantor has the requisite
corporate power and authority to enter into and to consummate the transactions
contemplated by this Guaranty, and otherwise to carry out its obligations
hereunder. The execution and delivery of this Guaranty by the Guarantor and the
consummation by it of the transactions contemplated hereby have been duly
authorized by all requisite corporate action on the part of the Guarantor. This
Guaranty has been duly executed and delivered by the Guarantor and constitutes
the valid and binding obligation of the Guarantor enforceable against the
Guarantor in accordance with its terms, except as such enforceability may be
limited by applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation or similar laws relating to, or affecting generally the enforcement
of, creditors' rights and remedies or by other equitable principles of general
application.

            (c) No Conflicts. The execution, delivery and performance of this
Guaranty by the Guarantor and the consummation by the Guarantor of the
transactions contemplated thereby do not and will not (i) conflict with or
violate any provision of its Certificate of Incorporation or By-laws or (ii)
conflict with, constitute a default (or an event which with notice or lapse of
time or both would become a default) under, or give to others any rights of
termination, amendment, acceleration or cancellation of, any agreement,
indenture or instrument to which the Guarantor is a party, or (iii) result in a
violation of any law, rule, regulation, order, judgment, injunction, decree or
other restriction of any court or governmental authority to which the Guarantor
is subject (including Federal and state securities laws and regulations), or by
which any material property or asset of the Guarantor is bound or affected,
except in the case of each of clauses (ii) and (iii), such conflicts, defaults,
terminations, amendments, accelerations, cancellations and violations as could
not, individually or in the aggregate, have or result in a Material Adverse
Effect. The business of the Guarantor is not being conducted in violation of any
law, ordinance or regulation of any governmental authority, except for
violations which, individually or in the aggregate, do not have a Material
Adverse Effect.

            (d) Consents and Approvals. The Guarantor is not required to obtain
any consent, waiver, authorization or order of, or make any filing or
registration with, any court or other federal, state, local, foreign or other
governmental authority or other person in connection with the execution,
delivery and performance by the Guarantor of this Guaranty.

                                       5
<PAGE>

            (e) Purchase Agreement. The representations and warranties of the
Company set forth in the Purchase Agreement as they relate to such Guarantor,
each of which is hereby incorporated herein by reference, are true and correct
as of each time such representations are deemed to be made pursuant to such
Purchase Agreement, and the Purchasers shall be entitled to rely on each of them
as if they were fully set forth herein, provided, that each reference in each
such representation and warranty to the Company's knowledge shall, for the
purposes of this Section 3, be deemed to be a reference to such Guarantor's
knowledge.

            (f) Foreign Law. Each Guarantor has consulted with appropriate
foreign legal counsel with respect to any of the above representations for which
non-U.S. law is applicable. Such foreign counsel have advised each applicable
Guarantor that such counsel knows of no reason why any of the above
representations would not be true and accurate. Such foreign counsel were
provided with copies of this Subsidiary Guarantee and the Transaction Documents
prior to rendering their advice.

      4. Covenants.

            (a) Each Guarantor covenants and agrees with the Purchasers that,
from and after the date of this Guarantee until the Obligations shall have been
paid in full, such Guarantor shall take, and/or shall refrain from taking, as
the case may be, each commercially reasonable action that is necessary to be
taken or not taken, as the case may be, so that no Event of Default is caused by
the failure to take such action or to refrain from taking such action by such
Guarantor.

            (b) So long as any of the Obligations are outstanding, each
Guarantor will not directly or indirectly on or after the date of this
Guarantee:

                  (i) except with the prior written consent of the Agent (as
                  defined in the Security Agreement), enter into, create, incur,
                  assume or suffer to exist any indebtedness for borrowed money
                  of any kind, including but not limited to, a guarantee, on or
                  with respect to any of its property or assets now owned or
                  hereafter acquired or any interest therein or any income or
                  profits therefrom that is senior to, or pari passu with, in
                  any respect, such Guarantor's obligations hereunder;

                  (ii) enter into, create, incur, assume or suffer to exist any
                  liens of any kind, on or with respect to any of its property
                  or assets now owned or hereafter acquired or any interest
                  therein or any income or profits therefrom that is senior to,
                  in any respect, such Guarantor's obligations hereunder;

                  (iii) amend its certificate of incorporation, bylaws or other
                  charter documents so as to adversely affect any rights of the
                  Holder hereunder;

                  (iv) repay, repurchase or offer to repay, repurchase or
                  otherwise acquire more than a de minimis number of shares of
                  its Common Stock or Common Stock Equivalents;

                  (v) enter into any agreement with respect to any of the
                  foregoing; or

                                       6
<PAGE>

                  (vi) pay cash dividends on any equity securities of the
                  Company.

      5. Miscellaneous.

            (a) Amendments in Writing. None of the terms or provisions of this
Guarantee may be waived, amended, supplemented or otherwise modified except in
writing by the Purchasers.

            (b) Notices. All notices, requests and demands to or upon the
Purchasers or any Guarantor hereunder shall be effected in the manner provided
for in the Purchase Agreement; provided that any such notice, request or demand
to or upon any Guarantor shall be addressed to such Guarantor at its notice
address set forth on Schedule 5(b).

            (c) No Waiver By Course Of Conduct; Cumulative Remedies. The
Purchasers shall not by any act (except by a written instrument pursuant to
Section 5(a)), delay, indulgence, omission or otherwise be deemed to have waived
any right or remedy hereunder or to have acquiesced in any default under the
Transaction Documents or Event of Default. No failure to exercise, nor any delay
in exercising, on the part of the Purchasers, any right, power or privilege
hereunder shall operate as a waiver thereof. No single or partial exercise of
any right, power or privilege hereunder shall preclude any other or further
exercise thereof or the exercise of any other right, power or privilege. A
waiver by the Purchasers of any right or remedy hereunder on any one occasion
shall not be construed as a bar to any right or remedy which the Purchasers
would otherwise have on any future occasion. The rights and remedies herein
provided are cumulative, may be exercised singly or concurrently and are not
exclusive of any other rights or remedies provided by law.

            (d) Enforcement Expenses; Indemnification.

                  (i) Each Guarantor agrees to pay, or reimburse the Purchasers
                  for, all its costs and expenses incurred in collecting against
                  such Guarantor under the guarantee contained in Section 2 or
                  otherwise enforcing or preserving any rights under this
                  Guarantee and the other Transaction Documents to which such
                  Guarantor is a party, including, without limitation, the
                  reasonable fees and disbursements of counsel to the
                  Purchasers.

                  (ii) Each Guarantor agrees to pay, and to save the Purchasers
                  harmless from, any and all liabilities with respect to, or
                  resulting from any delay in paying, any and all stamp, excise,
                  sales or other taxes which may be payable or determined to be
                  payable in connection with any of the transactions
                  contemplated by this Guarantee.

                  (iii) Each Guarantor agrees to pay, and to save the Purchasers
                  harmless from, any and all liabilities, obligations, losses,
                  damages, penalties, actions, judgments, suits, costs, expenses
                  or disbursements of any kind or nature whatsoever with respect
                  to the execution, delivery, enforcement, performance and
                  administration of this Guarantee to the extent the Company
                  would be required to do so pursuant to the Purchase Agreement.

                                       7
<PAGE>

                  (iv) The agreements in this Section shall survive repayment of
                  the Obligations and all other amounts payable under the
                  Purchase Agreement and the other Transaction Documents.

            (e) Successor and Assigns. This Guarantee shall be binding upon the
successors and assigns of each Guarantor and shall inure to the benefit of the
Purchasers and their respective successors and assigns; provided that no
Guarantor may assign, transfer or delegate any of its rights or obligations
under this Guarantee without the prior written consent of the Purchasers.

            (f) Set-Off. Each Guarantor hereby irrevocably authorizes the
Purchasers at any time and from time to time while an Event of Default under any
of the Transaction Documents shall have occurred and be continuing, without
notice to such Guarantor or any other Guarantor, any such notice being expressly
waived by each Guarantor, to set-off and appropriate and apply any and all
deposits, credits, indebtedness or claims, in any currency, in each case whether
direct or indirect, absolute or contingent, matured or unmatured, at any time
held or owing by the Purchasers to or for the credit or the account of such
Guarantor, or any part thereof in such amounts as the Purchasers may elect,
against and on account of the obligations and liabilities of such Guarantor to
the Purchasers hereunder and claims of every nature and description of the
Purchasers against such Guarantor, in any currency, whether arising hereunder,
under the Purchase Agreement, any other Transaction Document or otherwise, as
the Purchasers may elect, whether or not the Purchasers have made any demand for
payment and although such obligations, liabilities and claims may be contingent
or unmatured. The Purchasers shall notify such Guarantor promptly of any such
set-off and the application made by the Purchasers of the proceeds thereof,
provided that the failure to give such notice shall not affect the validity of
such set-off and application. The rights of the Purchasers under this Section
are in addition to other rights and remedies(including, without limitation,
other rights of set-off) which the Purchasers may have.

            (g) Counterparts. This Guarantee may be executed by one or more of
the parties to this Guarantee on any number of separate counterparts (including
by telecopy), and all of said counterparts taken together shall be deemed to
constitute one and the same instrument.

            (h) Severability. Any provision of this Guarantee which is
prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction,
be ineffective to the extent of such prohibition or unenforceability without
invalidating the remaining provisions hereof, and any such prohibition or
unenforceability in any jurisdiction shall not invalidate or render
unenforceable such provision in any other jurisdiction.

            (i) Section Headings. The Section headings used in this Guarantee
are for convenience of reference only and are not to affect the construction
hereof or be taken into consideration in the interpretation hereof.

            (j) Integration. This Guarantee and the other Transaction Documents
represent the agreement of the Guarantors and the Purchasers with respect to the
subject matter hereof and thereof, and there are no promises, undertakings,
representations or warranties by the Purchasers relative to subject matter
hereof and thereof not expressly set forth or referred to herein or in the other
Transaction Documents.

                                       8
<PAGE>

            (k) Governing Law. THIS GUARANTEE SHALL BE GOVERNED BY, AND
CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK
WITHOUT REGARD TO ANY PRINCIPLES OF CONFLICTS OF LAWS.

            (l) Submission to Jurisdictional; Waiver. Each Guarantor hereby
irrevocably and unconditionally:

                  (i) submits for itself and its property in any legal action or
                  proceeding relating to this Guarantee and the other
                  Transaction Documents to which it is a party, or for
                  recognition and enforcement of any judgment in respect
                  thereof, to the non-exclusive general jurisdiction of the
                  Courts of the State of New York, located in New York County,
                  New York, the courts of the United States of America for the
                  Southern District of New York, and appellate courts from any
                  thereof;

                  (ii) consents that any such action or proceeding may be
                  brought in such courts and waives any objection that it may
                  now or hereafter have to the venue of any such action or
                  proceeding in any such court or that such action or proceeding
                  was brought in an inconvenient court and agrees not to plead
                  or claim the same;

                  (iii) agrees that service of process in any such action or
                  proceeding may be effected by mailing a copy thereof by
                  registered or certified mail (or any substantially similar
                  form of mail), postage prepaid, to such Guarantor at its
                  address referred to in the Purchase Agreement or at such other
                  address of which the Purchasers shall have been notified
                  pursuant thereto;

                  (iv) agrees that nothing herein shall affect the right to
                  effect service of process in any other manner permitted by law
                  or shall limit the right to sue in any other jurisdiction; and

                  (v) waives, to the maximum extent not prohibited by law, any
                  right it may have to claim or recover in any legal action or
                  proceeding referred to in this Section any special, exemplary,
                  punitive or consequential damages.

            (m) Acknowledgements. Each Guarantor hereby acknowledges that:

                  (i) it has been advised by counsel in the negotiation,
                  execution and delivery of this Guarantee and the other
                  Transaction Documents to which it is a party;

                  (ii) the Purchasers have no fiduciary relationship with or
                  duty to any Guarantor arising out of or in connection with
                  this Guarantee or any of the other Transaction Documents, and
                  the relationship between the Guarantors, on the one hand, and
                  the Purchasers, on the other hand, in connection herewith or
                  therewith is solely that of debtor and creditor; and

                                       9
<PAGE>

                  (iii) no joint venture is created hereby or by the other
                  Transaction Documents or otherwise exists by virtue of the
                  transactions contemplated hereby among the Guarantors and the
                  Purchasers.

            (n) Additional Guarantors. The Company shall cause each of its
subsidiaries formed or acquired on or subsequent to the date hereof to become a
Guarantor for all purposes of this Guarantee by executing and delivering an
Assumption Agreement in the form of Annex 1 hereto.

            (o) Release of Guarantors. Subject to Section 2.6, each Guarantor
will be released from all liability hereunder concurrently with the repayment in
full of all amounts owed under the Purchase Agreement, the Debentures and the
other Transaction Documents.

            (p) Seniority. Subject to, with respect to PracticeXpert Systems,
Inc., the prior claim of Citibank N.A. pursuant to the promissory notes in the
aggregate amount of $4 million issued by PracticeXpert Systems, Inc. to Citibank
N.A. as set forth on Schedule 5(p) hereto, the Obligations of each of the
Guarantors hereunder rank senior in priority to any other unsecured Indebtedness
(as defined in the Purchase Agreement) of such Guarantor.

            (q) Waiver of Jury Trial. EACH GUARANTOR AND, BY ACCEPTANCE OF THE
BENEFITS HEREOF, THE PURCHASERS, HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVE
TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING RELATING TO THIS GUARANTEE AND
FOR ANY COUNTERCLAIM THEREIN.

      IN WITNESS WHEREOF, each of the undersigned has caused this Guarantee to
be duly executed and delivered as of the date first above written.

                             PracticeXpert of Oklahoma, Inc.

                                      By: /s/ Jonathan Doctor
                                          --------------------------------------
                                               Name:  Jonathan Doctor
                                               Title: President

                             PracticeXpert of California, Inc.

                                      By: /s/ Jonathan Doctor
                                         ---------------------------------------
                                               Name:  Jonathan Doctor
                                               Title: President

                             PracticeXpert of Idaho, Inc.

                                      By: /s/ Jonathan Doctor
                                         ---------------------------------------
                                               Name:  Jonathan Doctor
                                               Title: President

                                       10
<PAGE>

                             PracticeXpert of Texas, Inc.

                                      By: /s/ Jonathan Doctor
                                         ---------------------------------------
                                               Name:  Jonathan Doctor
                                               Title: President

                             PracticeXpert of West Virginia, Inc.

                                      By: /s/ Jonathan Doctor
                                         ---------------------------------------
                                               Name:  Jonathan Doctor
                                               Title: President

                             PracticeXpert Systems, Inc.

                                      By: /s/ Jonathan Doctor
                                         ---------------------------------------
                                               Name:  Jonathan Doctor
                                               Title: President

                             Practice Xpert Services Corp .

                                      By: /s/ Jonathan Doctor
                                         ---------------------------------------
                                               Name:  Jonathan Doctor
                                               Title: President

                                       11
<PAGE>

                                   SCHEDULE 1

                                   GUARANTORS

            The following are the names, notice addresses and jurisdiction of
organization of each Guarantor.

                                             JURISDICTION OF          COMPANY
                                             INCORPORATION            OWNED BY
                                                                      PERCENTAGE

PracticeXpert of Oklahoma, Inc.              Oklahoma                 100%
PracticeXpert of California, Inc.            California               100%
PracticeXpert of Idaho, Inc.                 Idaho                    100%
PracticeXpert of Texas, Inc.                 Texas                    100%
PracticeXpert of West Virginia, Inc.         West Virginia            100%
PracticeXpert Systems, Inc.                  Virginia                 100%
Practice Xpert Services Corp.                California               100%

                                       12
<PAGE>

Schedule 5(p)

Promissory Note dated 06/06/05 in the aggregate principal amount of $3,776,000
Promissory Note dated 07/14/05 in the aggregate principal amount of $50,000
Promissory Note dated 07/25/05 in the aggregate principal amount of $100,000
Promissory Note dated 07/29/05 in the aggregate principal amount of $74,000

                                       13
<PAGE>

                                   Annex 1 to
                              SUBSIDIARY GUARANTEE

ASSUMPTION AGREEMENT, dated as of ____ __, ______ made by
______________________________, a ______________ corporation (the "Additional
Guarantor"), in favor of the Purchasers pursuant to the Purchase Agreement
referred to below. All capitalized terms not defined herein shall have the
meaning ascribed to them in such Purchase Agreement.

                                  WITNESSETH :

      WHEREAS, PracticeXpert, Inc. a Nevada corporation (the "Company") and the
Purchasers have entered into a Securities Purchase Agreement, dated as of May
19, 2006 (as amended, supplemented or otherwise modified from time to time, the
"Purchase Agreement");

      WHEREAS, in connection with the Purchase Agreement, the Company and its
Subsidiaries (other than the Additional Guarantor) have entered into the
Subsidiary Guarantee, dated as of May 19, 2006 (as amended, supplemented or
otherwise modified from time to time, the "Guarantee") in favor of the
Purchasers;

      WHEREAS, the Purchase Agreement requires the Additional Guarantor to
become a party to the Guarantee; and

      WHEREAS, the Additional Guarantor has agreed to execute and deliver this
Assumption Agreement in order to become a party to the Guarantee;

                          NOW, THEREFORE, IT IS AGREED:

      1. Guarantee. By executing and delivering this Assumption Agreement, the
Additional Guarantor, as provided in Section 5.1(n) of the Guarantee, hereby
becomes a party to the Guarantee as a Guarantor thereunder with the same force
and effect as if originally named therein as a Guarantor and, without limiting
the generality of the foregoing, hereby expressly assumes all obligations and
liabilities of a Guarantor thereunder. The information set forth in Annex 1-A
hereto is hereby added to the information set forth in Schedule 1 to the
Guarantee. The Additional Guarantor hereby represents and warrants that each of
the representations and warranties contained in Section 3 of the Guarantee is
true and correct on and as the date hereof as to such Additional Guarantor
(after giving effect to this Assumption Agreement) as if made on and as of such
date.

      2. Governing Law. THIS ASSUMPTION AGREEMENT SHALL BE GOVERNED BY, AND
CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

                                       14
<PAGE>

      IN WITNESS WHEREOF, the undersigned has caused this Assumption Agreement
to be duly executed and delivered as of the date first above written.

                                                       [ADDITIONAL GUARANTOR]

                                                       By:
                                                       Name:
                                                       Title:

                                       15COOPERATIVE
      RESEARCH AND DEVELOPMENT AGREEMENT

     

    This
      Cooperative Research and Development Agreement, hereinafter referred to as
      the
“CRADA,”
      consists of this Cover Page, an attached agreement, and various Appendices
      referenced in the agreement. This Cover Page serves to identify the parties
      to
      this CRADA:

     

    This
      CRADA is made and entered into by and among:

     

    (1) The
      Uniformed Services University of the Health Sciences (which includes the Armed
      Forces Radiobiology Research Institute (“AFRRI”)),
      an
      institution of higher learning within the Department of Defense, an agency
      of
      the United States Government, hereinafter referred to as “USU,”
      located at 4301 Jones Bridge Road, Bethesda, Maryland 20814-4799;

     

    (2) The
      Henry
      M. Jackson Foundation for the Advancement of Military Medicine, Inc., a tax-
      exempt corporation organized and existing under the laws of the State of
      Maryland, hereinafter referred to as the “Foundation,”
with
      offices located at 1401 Rockville Pike, Suite 600, Rockville, Maryland 20852;
      and the following two “Collaborators”:

     

    (3) The
      Cleveland Clinic Foundation (which includes the Lernerer Research Institute),
      hereinafter referred to as “CCF”,
      with
      offices at 9500 Euclid Avenue, Cleveland, Ohio 44195; and

     

    (4) Cleveland
      BioLabs, Inc., hereinafter referred to as “CBL”,
      located at 10265 Carnegie Avenue, Cleveland, Ohio 44106.

     

    WHEREAS,
      The
      Federal Technology Transfer Act of 1986, as amended, 15 U.S.C. § 3710a
et seq.,
      provides for making Federal laboratories’ developments accessible to private
      industry and to state and local governments, and for the improvement of the
      economic, environmental, and social well-being of the United States by
      stimulating the civil utilization of Federally-funded technology
      developments;

     

    WHEREAS,
      USU/AFFRI has extensive expertise, capabilities, and information in the areas
      of
      radioprotectants and radiation casualty management;

     

    WHEREAS,
      the
      Foundation has an agreement with USU to support the development and
      commercialization of scientific and medical technologies, and pursuant to such
      agreement the Foundation acts as patent management organization for USU and
      has
      the authority, on behalf of USU, to enter into research and licensing agreements
      and receive and distribute funds in connection therewith;

     

    WHEREAS,
      it is
      the intent of USU and the Foundation to promote the goals of the Federal
      Technology Transfer Act and collaborate with private parties to promote the
      development, manufacture, and marketing of products and services that utilize
      transferred technology for the benefit of mankind; and

     

    WHEREAS,
      the
      Collaborators have the interest, resources, capabilities, and technical
      expertise to transition the results of USU/AFFRI research and development for
      public use.

     

    
      
        	USU/AFRRI - HJF - CCF - CBL CRADA 	
                 PROPRIETARY/CONFIDENTIAL
                  INFORMATION

              

      

    

    
      
        
          

        

      

      
        
        

      

    

    NOW,
      THEREFORE,
      in
      consideration of the mutual covenants contained herein, and for other good
      and
      valuable consideration, the receipt and sufficiency of which are hereby
      expressly acknowledged, the Parties agree as follows:

     

    ARTICLE
      1

    INTRODUCTION

     

    1.1. This
      CRADA shall be effective as of August 01, 2004 (the “Effective
      Date”).
      The
      research and development activities that will be undertaken by each of the
      Parties in the course of this CRADA are summarized in the Research Plan
      (“RP”)
      attached as Appendix
      A.
      The
      funding and staffing commitments of the Parties are set forth in Appendix
      B.
      This
      CRADA is made under the authority of the Federal Technology Transfer Act, 15
      U.S.C. §3710a, and is governed by its terms.

     

    ARTICLE
      2

    DEFINITIONS

     

    As
      used
      in this CRADA, the following terms shall have the indicated
      meanings:

     

    2.1. “Cooperative
      Research and Development Agreement”
or
      “CR.ADA”
means
      this agreement, with its Appendices, entered into by the USU pursuant to the
      Federal Technology Transfer Act of 1986, as amended, 15 U.S.C. § 3710a
et
      seq.,
      and
      Executive Order 12591 of April 10, 1987.

     

    2.2. “Government”
means
      the government of the United States of America as represented through the USU,
      which is a Party to this CRADA.

     

    2.3. “IP”
means
      intellectual property.

     

    2.4. “Principal
      Investigator(s)”
or
      “PI(s)”
means
      the person(s) designated respectively by the Parties to this CRADA who will
      be
      responsible for the scientific and technical conduct of the RP.

     

    2.5. “Proprietary/Confidential
      Information”
means
      confidential scientific, business, or financial information that is treated
      as
      proprietary or confidential by the disclosing Party provided that such
      information does not include:

     

    2.5.1. information
      that is publicly known or available from other sources who are not under a
      confidentiality obligation to the source of the information;

     

    2.5.2. information
      that has been made available by its owners to others without a confidentiality
      obligation;

     

    2.5.3. information
      that is already known by or available to the receiving Party without a
      confidentiality obligation; or

    
      
        	USU/AFRRI - HJF - CCF - CBL CRADA 	
                 PROPRIETARY/CONFIDENTIAL
                  INFORMATION

              

      

    

    
      
        
          

        

      

      
        
        

      

    

    2.5.4. information
      that has been independently developed by the receiving Party, without any
      reference to or use of the information received by it under this CRADA as
      evidenced by written records of the receiving Party.

     

    2.6. “Research
      Materials”
means
      all tangible materials other than Subject Data first produced in the performance
      of this CRADA.

     

    2.7. “Research
      Plan”
or
      “RP”
means
      the statement in Appendix
      A
      of the
      respective research and development commitments of the Parties to this
      CRADA.

     

    2.8. “Subject
      Invention”
means
      any invention of a Party or Parties conceived or first actually reduced to
      practice in the performance of the Research Plan of this CRADA that is or may
      be
      patentable or otherwise protected under title 35, United States Code, or any
      novel variety of plant that is or may be protectable under the Plant Variety
      Protection Act (7 U.S.C. § 2321 et seq.).

     

    2.9. “Subject
      Data”
means
      all recorded information first produced by any of the Parties in the performance
      of this CRADA.

     

    ARTICLE
      3

    COOPERATIVE
      RESEARCH

     

    3.1. Principal
      Investigators.
      The USU
      laboratory identified in the RP will perform USU research work under this CRADA,
      and the USU and the USU PI designated in the RP will be responsible for the
      scientific and technical conduct of this project on behalf of USU. The
      Collaborator PI designated in the RP who will be responsible for the scientific
      and technical conduct of this project on behalf of the
      Collaborator.

     

    3.2. Research
      Plan Changes.
      The RP
      may be modified only by express written agreement of the Parties.

     

    3.3. Compliance
      With Laws.
      In
      conducting the research activities under this CRADA, each Party and its
      employees and agents shall comply with all federal, state, and local laws,
      ordinances, rules, and regulations applicable to such activities. The use and
      dissemination of information, materials, and Subject Data exchanged under this
      CRADA will be in accordance with all federal laws and regulations, including
      but
      not limited to the Federal Food, Drug and Cosmetic Act, the Biological Products
      Section of the Public Health Service Act, and the regulations issued thereunder,
      the International Traffic in Arms Regulations (22 CFR Part 120 et seq.),
      and
      the Department of Commerce Export Regulations (15 CFR Part 730 et seq.)
      Nothing in this CRADA shall be construed as a license to export such
      information, materials, or Subject Data or to permit any disclosure in violation
      of law, regulation, or Department of Defense policy. Each exporting Party is
      responsible for obtaining any export licenses that may be required by federal
      law.

     

    
      
        	USU/AFRRI - HJF - CCF - CBL CRADA 	
                 PROPRIETARY/CONFIDENTIAL
                  INFORMATION

              

      

    

    
      
        
          

        

      

      
        
        

      

    

    ARTICLE
      4

    REPORTS

     

    4.1. Interim
      Reports.
      USU and
      the Collaborators shall exchange formal written interim progress reports on
      a
      schedule agreed to by the PIs, but at least within twelve- (12) months after
      this CRADA becomes effective and at least once within every twelve- (12) month
      period thereafter.

     

    4.2. Final
      Reports.
      USU and
      the Collaborators shall exchange final reports of their results within four-
      (4)
      months after completing the projects described in the RP or after the expiration
      or termination of this CRADA, whichever first occurs. Interim and final reports
      shall (i) set forth the technical progress made, identifying such problems
      as
      may have been encountered, (ii) identify Subject Inventions pursuant to Section
      6.1, and (iii) in the case of interim reports, establish goals and objectives
      requiring further effort, and describe any proposed modifications to the
      Research Plan pursuant to Section 3.2.

     

    ARTICLE
      5

    FINANCIAL
      AND STAFFING OBLIGATIONS

     

    5.1. Contributions
      of the Parties.
      The
      required contributions of the Parties, including payment schedules, if
      applicable, are set forth in Appendix
      B.
      Neither
      USU nor the Foundation shall be obligated to perform any of the research
      specified herein or to take any other action required by this CRADA if any
      funding as set forth in Appendix
      B
      is not
      provided.

     

    5.2. Authority
      of the Parties.
      None of
      the Parties hereto shall have the authority, express or implied, to bind or
      commit any of the other Parties to perform or provide in any manner, or to
      pay
      money for, services or material with respect to any third party unless
      authorized in writing by such other Party’s designated representative. Nothing
      contained herein shall render any Party liable for any debts or obligations
      of
      the other Parties, except as otherwise specifically provided in this
      CRADA.

     

    5.3. Accounting
      Records.
      USU
      shall maintain separate and distinct current accounts, records, and other
      evidence supporting all its obligations under this CRADA, and shall provide
      the
      Collaborators a final fiscal report pursuant to Section 4.2. USU shall return
      unused funds, if any, to the Collaborators when USU sends the final fiscal
      report.

     

    5.4. Capital
      Equipment.
      Equipment purchased by USU with funds provided by the Collaborators shall be
      the
      property of USU. All capital equipment provided under this CRADA by one Party
      for the use of another Party remains the property of the providing Party unless
      other disposition is mutually agreed in writing by the Parties. If title to
      this
      equipment remains with the providing Party, that Party is responsible for
      maintenance of the equipment and the costs of its transportation to and from
      the
      site where it will be used.

     

    ARTICLE
      6

    IP
      INTERESTS

     

    6.1. Reporting
      of Subject Inventions.
      Each
      Party shall promptly report to the other Parties in writing each Subject
      Invention and any patent applications filed thereon. Each Party shall report
      all
      Subject Inventions to the other Parties in sufficient detail to determine
      inventorship. Such reports shall be treated as Proprietary/Confidential
      Information in accordance with Section 8.4.

     

    
      
        	USU/AFRRI - HJF - CCF - CBL CRADA 	
                 PROPRIETARY/CONFIDENTIAL
                  INFORMATION

              

      

    

    
      
        
          

        

      

      
        
        

      

    

    6.2. Title
      to and Ownership of Subject Inventions.
      Inventorship shall be determined in accordance with the patent laws of the
      United States of America. All Subject Inventions conceived or first actually
      reduced to practice solely by an employee of a Party shall belong to the
      employee (or to the employee’s employer if the employee and the employer have so
      agreed). Two or more Parties shall jointly own a Subject Invention if each
      of
      such Parties employed at least one inventor thereof at the time of its
      conception or first actual reduction to practice, provided that each Party
      has
      acquired the interest of its respective employee(s) in the Subject Invention.
      Each Party shall cooperate with the other Party(ies) to obtain inventor
      signatures on patent applications, assignments, and other documents required
      to
      secure IP protection.

     

    6.3. Filing
      of Patent Applications.
      Each
      Party shall have the primary responsibility for filing patent or other IP
      applications on the Subject Inventions of its own employee(s) in a timely
      manner, at its own expense, and after consultation with the other Parties.
      Notwithstanding the foregoing, by mutual agreement, the Parties may identify
      which Party shall file a patent application on any Subject Invention. The
      Parties will consult and mutually determine a filing strategy for jointly owned
      Subject Inventions.

     

    6.4. Prosecution
      of Intellectual Property Applications.
      Within
      one- (1) month of receipt or filing, each Party shall provide the other Parties
      with copies of the applications and all documents received from or filed with
      the relevant patent or other IP office in connection with the prosecution of
      such applications. Each Party shall also provide the other Parties with the
      power to inspect and make copies of all documents retained in the patent or
      other IP application files by the applicable patent or other IP office. Where
      licensing is contemplated by the Collaborators, the Parties agree to consult
      with one another with respect to the prosecution of applications for USU and
      Foundation Subject Inventions and jointly owned Subject Inventions described
      in
      Section 6.2.

     

    6.5. Copyright
      License to the Government.
      The
      Collaborators hereby grant to the Government and its agents a nonexclusive,
      nontransferable, irrevocable, world-wide, royalty-free license to all of the
      Collaborators’ rights set forth in 17 U.S.C. § 106 and § 905 in and to any and
      all works of authorship and mask works, respectively, prepared pursuant to
      this
      CRADA.

     

    6.6. Copyright
      Statement.
      The
      Collaborators shall include the following statement on any work of authorship
      or
      mask work created in the performance of this CRADA:

     

    “The
      U.S.
      Government has a copyright license in this work pursuant to a CRADA with The
      Cleveland Clinic Foundation and Cleveland BioLabs, Inc.”

     

    ARTICLE
      7

    LICENSING

     

    7.1. No
      License in Government or Foundation Subject Inventions.
      Collaborators understand and agree that they acquire under this Agreement no
      property interest in any Government or Foundation [rights to any Subject
      Invention. USU and Foundation, in their discretion, respectively may offer
      a
      license or an option for a license to Government or Foundation IP rights in
      Subject Invention(s), but no such offer or commitment is made
      herein.

     

    
      
        
          	USU/AFRRI - HJF - CCF - CBL CRADA 	
                   PROPRIETARY/CONFIDENTIAL
                    INFORMATION

                

        

      

      
        
          

        

      

      
        
        

      

    

    7.2. License
      in Collaborator Subject Inventions.
      Pursuant to 15 U.S.C. § 3710a(b)(2), for Subject Inventions that, pursuant to
      Section 6.2, are either solely owned by one of the Collaborators or jointly
      owned by the two Collaborators, the Collaborator(s) grant(s) to the Government
      a
      nonexclusive, nontransferable, irrevocable, paid-up license to practice the
      Subject Invention or have the Subject Invention practiced throughout the world
      by or on behalf of the Government for research or other Government
      purposes.

     

    7.3. Joint
      Subject Inventions.
      Each
      Party shall have the right to use any Subject Invention that is jointly owned
      pursuant to Section 6.2 and to license its use to others in all
      fields.

     

    ARTICLE
      8

    PROPRIETARY
      RIGHTS AND PUBLICATION

     

    8.1. Right
      of Access and Use.
      The
      Parties agree to exchange all Subject Data produced in the course of research
      under this CRADA. The Parties agree to share Research Materials equally unless
      other disposition is mutually agreed. Each of the Parties to this CRADA shall
      have the right to use all Subject Data and Research Materials for their own
      purposes, consistent with their obligations under this CRADA.

     

    8.2. Ownership
      of Subject Data and Research Materials.
      Subject
      to the sharing requirements of Paragraph 8.1 and the regulatory filing
      requirements of Paragraph 8.3, the producing Party will retain ownership of
      and
      title to all Subject Data and all Research Materials produced solely by the
      producing Party’s investigator(s). Jointly developed Subject Data and Research
      Materials will be jointly owned.

     

    8.3. Dissemination
      of Subject Data and Research Materials.
      To the
      extent allowed under law, the Collaborators, Foundation, and USU agree to use
      reasonable efforts to keep Subject Data and Research Materials confidential
      until published or until corresponding patent applications are filed. Any
      information that would identify human subjects of research or patients will
      be
      maintained confidentially and in compliance with all applicable laws and
      regulations, including without limitation the Health Insurance Portability
      and
      Accountability Act of 1996 (HIPAA), as amended, and its implementing
      regulations. To the extent permitted by law, the Collaborators shall have the
      exclusive right to use any and all Subject Data in and for any regulatory filing
      by or on behalf of the Collaborators, except that Foundation and USU shall
      have
      the exclusive right to use Subject Data for that purpose, and authorize others
      to do so, if the CRADA is terminated or if the Collaborators abandon their
      commercialization efforts.

     

    8.4. Proprietary/Confidential
      Information.
      Each
      Party agrees to limit its disclosure of Proprietary/Confidential Information
      to
      the amount necessary to carry out the Research Plan of this CRADA, and shall
      place a confidentiality notice on all such information. Confidential oral
      communications shall be identified as such at time of disclosure and shall
      be
      reduced to writing within thirty- (30) days by the disclosing Party. Each Party
      receiving Proprietary/Confidential Information agrees that any information
      so
      designated shall be used by it only for the purposes described in the attached
      Research Plan. Any Party may object to the designation of information as
      Proprietary/Confidential Information by another Party. Subject Data and Research
      Materials developed solely by a Collaborator may be designated as
      Proprietary/Confidential Information when they are wholly separable from the
      Subject Data and Research Materials developed jointly with USU investigators
      and
      advance designation of such data and material categories is set forth in the
      RP.
      The exchange of other confidential information, e.g., patient-identifying data,
      should be similarly limited and treated.

     

    
      
        	USU/AFRRI - HJF - CCF - CBL CRADA 	
                 PROPRIETARY/CONFIDENTIAL
                  INFORMATION

              

      

    

    
      
        
          

        

      

      
        
        

      

    

    8.5. Protection
      of Proprietary/Confidential Information.
      Proprietary/Confidential Information shall not be disclosed, copied, reproduced,
      or otherwise made available to any other person or entity without the consent
      of
      the disclosing Party except as required under court order or the Freedom of
      Information Act (5 U.S.C. §552). Each Party shall protect the
      Proprietary/Confidential Information of each and all of the other Parties with
      at least the same degree of care used in the protection of its own
      Proprietary/Confidential Information of similar character (but no less a degree
      of care than a normally prudent business would exercise); none of the Parties
      may disclose the Proprietary/Confidential Information of any other Party without
      the prior written consent of that other Party except as specified below; each
      Party shall limit disclosure thereof to employees having a need to know in
      effectuating the purposes of this CRADA and who have been informed of the
      confidential nature thereof and the provisions of this Article; and upon
      termination of this CRADA (except to the extent otherwise provided in this
      CRADA
      or by written agreement of the Parties) each Party shall upon request deliver
      such Proprietary/Confidential Information preserved in physical form to the
      Party owning such information or, upon written consent of the owning Party,
      certify in writing its destruction. Each Party agrees that the other Parties
      are
      not liable for the disclosure of Proprietary/Confidential Information which,
      after notice to and consultation with the concerned Party, the other Party(ies)
      in possession of the Proprietary/Confidential Information determine may not
      be
      lawfully withheld, provided the concerned Party has been given an opportunity
      to
      seek a court order to enjoin disclosure.

     

    8.6. Duration
      of Confidentiality Obligation.
      The
      obligation to maintain the confidentiality of Proprietary/Confidential
      Information shall expire at the earlier of the date when the information is
      no
      longer Proprietary/Confidential Information as defined in Section 2.5 or five-
      (5) years after the expiration or termination date of this CRADA. Any Party
      may
      request an extension to this term when necessary to protect
      Proprietary/Confidential Information relating to products not yet
      commercialized.

     

    8.7. Publication.
      The
      Parties are encouraged to make publicly available the results of their research.
      In order to protect rights in Subject Inventions or Proprietary/Confidential
      Information, the Parties agree, during the term of this CRADA and for one-
      (1)
      year thereafter or such greater period as is required, to confer and consult
      prior to any publication or public disclosure of information about a Subject
      Invention, Subject Data, or Research Materials to ensure that no
      Proprietary/Confidential Information is released and that patent rights are
      not
      compromised. Before any Party submits a paper or abstract for publication or
      otherwise intends to publicly disclose information about a Subject Invention,
      Subject Data, or Research Materials, the other Parties shall be provided thirty-
      (30) days to review the proposed abstract, publication, presentation, or other
      document and object to any proposed release of information. For the purposes
      of
      this Section, the term “disclosure” shall include submission of any manuscripts
      for peer review prior to publication, as well as any oral, poster, or online
      presentation. It is the responsibility of the Party intending to make public
      disclosure to notify the other Parties of such intent.

     

    
      
        	
                USU/AFRRI - HJF - CCF - CBL CRADA 

              	
                 PROPRIETARY/CONFIDENTIAL
                  INFORMATION

              

      

    

    
      
        
          

        

      

      
        
        

      

    

    If
      a
      Party objects to a proposed public disclosure, that Party must so notify the
      other Parties within thirty- (30) days of receiving notice of intent to disclose
      publicly. If no timely objection is received by the Party intending to make
      public disclosure, concurrence is assumed. If a Party objects on the grounds
      that patent or other IP rights may be compromised, the publication or other
      disclosure shall be delayed for up to sixty- (60) additional days upon written
      request by any Party as necessary to preserve U.S. or foreign patent or other
      IP
      rights. A patent application must be filed by the responsible Party as
      determined by Section 6.3, at the expense of the objecting Party, within ninety-
      (90) days of the date of notification of intent to make public disclosure,
      or by
      another date mutually agreed to by the Parties.

     

    ARTICLE
      9

    REPRESENTATIONS
      AND WARRANTIES

     

    9.1. Representations
      and Warranties of USU.
      USU
      hereby represents and warrants that the official signing this CRADA has
      authority to do so.

     

    9.2. Representations
      and Warranties of Foundation.
      Foundation hereby represents and warrants that the official signing this CRADA
      has authority to do so.

     

    9.3. Representations
      and Warranties of the Collaborators.
      Each
      Collaborator hereby represents and warrants that it has the requisite power
      and
      authority to enter into this CRADA and to perform according to its terms, and
      that the Collaborator’s official signing this CRADA has authority to do so. Each
      Collaborator further represents that it is financially able to satisfy all
      of
      its funding commitments made in Appendix
      B.

     

    ARTICLE
      10

    TERMINATION

     

    10.1. Termination
      By Mutual Consent.
      The
      Parties may terminate this CRADA, or portions thereof, at any time by mutual
      written consent. In such event the Parties shall specify the disposition of
      all
      property, Subject Inventions, patent or other IP applications, and other results
      of work accomplished or in progress, arising from or performed under this CRADA,
      all in accordance with the rights granted to the Parties under the terms of
      this
      CRADA.

     

    10.2. Unilateral
      Termination.
      Any one
      of the Parties hereto may unilaterally terminate this entire CRADA at any time
      by giving written notice to the other Parties at least thirty- (30) days prior
      to the desired termination date, and any rights accrued in property, patents
      or
      other IP rights shall be disposed of as provided in paragraph 10.1, except
      that
      in the event of unilateral termination by a Collaborator, USU may, at its
      option, retain funds previously transferred by either or both of the
      Collaborators to USU for use in completing the Research Plan solely or with
      another partner.

     

    10.3. New
      Commitments.
      No
      Party shall make new commitments related to this CRADA after a mutual
      termination or notice of a unilateral termination and shall, to the extent
      feasible, cancel all outstanding commitments and contracts by the termination
      date. Notwithstanding the foregoing, the Foundation and USU may, at their sole
      option and discretion, waive this requirement for any Parties they so choose
      if
      both Foundation and USU agree that such waiver is warranted.

     

    
      
        
          	USU/AFRRI - HJF - CCF - CBL CRADA 	
                   PROPRIETARY/CONFIDENTIAL
                    INFORMATION

                

        

      

      
        
          

        

      

      
        
        

      

    

    10.4. Termination
      Costs.
      Concurrently with the exchange of final reports pursuant to Sections 4.2 and
      5.3, USU shall submit to the Collaborators for payment a statement of all costs
      incurred prior to the date of termination and for all reasonable termination
      costs including the cost of returning Collaborators property or removal of
      abandoned property, for which the Collaborators shall be
      responsible.

     

    ARTICLE
      11

    DISPUTES

     

    11.1. Settlement.
      Any
      dispute arising under this CRADA that is not disposed of by agreement of the
      Principal Investigators shall be submitted jointly to the signatories of this
      CRADA. If the signatories are unable to jointly resolve the dispute within
      thirty- (30) days after notification thereof, the designated USU official (or
      his/her designee or successor) shall propose a resolution. Nothing in this
      Article shall prevent any Party from pursuing any additional administrative
      remedies that may be available and, after exhaustion of such administrative
      remedies and after fifteen- (15) days have passed following the proposal of
      the
      designated USU official, pursuing all available judicial remedies.

     

    11.2. Continuation
      of Work.
      Pending
      the resolution of any dispute or claim pursuant to this Article, the Parties
      agree that performance of all obligations shall be pursued diligently in
      accordance with the direction of the USU signatory.

     

    ARTICLE
      12

    LIABILITY

     

    12.1. Property.
      The
      Government shall not be responsible for damages to any Collaborator property
      provided to USU, where the Collaborator retains title to the property, or any
      property acquired by any Collaborator for its own use pursuant to this
      CRADA.

     

    12.2. NO
      WARRANTY.
      EXCEPT
      AS SPECIFICALLY STATED IN ARTICLE 9, THE PARTIES MAKE NO EXPRESS OR IMPLIED
      WARRANTY AS TO ANY MATTER WHATSOEVER, INCLUDING THE CONDITIONS OF THE RESEARCH
      OR ANY INVENTION OR PRODUCT, WHETHER TANGIBLE OR INTANGIBLE, MADE, OR DEVELOPED
      UNDER THIS CRADA, OR THE OWNERSHIP, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR
      PURPOSE OF THE RESEARCH OR ANY INVENTION OR PRODUCT.

     

    12.3. Liability
      and Indemnification.
      In
      general, each Party shall be responsible for its own losses, obligations,
      liabilities, costs, and expenses of every kind incurred by that Party or any
      of
      its officers, directors, employees, or agents. Each Party shall secure its
      own
      workers’ compensation, unemployment compensation, or like insurance for its
      employees as required by law. Each Collaborator agrees to hold the Government
      (including USU/AFRRI) and the Foundation harmless and to indemnify the
      Government and the Foundation for all liabilities, demands, damages, expenses,
      and losses arising out of the use by that Collaborator for any purpose of the
      Subject Data, Research Materials, and/or Subject Inventions produced in whole
      or
      part by USU or Foundation employees under this CRADA, unless due to the
      negligence or willful misconduct of USU, the Foundation, or the employees or
      agents of either. Each Collaborator shall be liable for any claims or damages
      it
      incurs in connection with this CRADA. USU has no authority or obligation to
      indemnify the Collaborators. To the extent authorized under the provisions
      of
      the Federal Tort Claims Act, including 28 U.S.C. § 2671-2680, the Government
      will be liable for any loss, claim, damage, or expense caused by the negligent
      or wrongful act or omission of any employee of the Department of Defense or
      any
      member of the United States Armed Forces while acting within the scope of his
      or
      her office or employment.

     

    
      
        
          	USU/AFRRI - HJF - CCF - CBL CRADA 	
                   PROPRIETARY/CONFIDENTIAL
                    INFORMATION

                

        

      

      
        
          

        

      

      
        
        

      

    

    12.4. Force
      Majeure.
      No
      Party shall be liable for any unforeseeable event beyond its reasonable control
      not caused by the fault or negligence of such Party, which causes such Party
      to
      be unable to perform its obligations under this CRADA, and which it has been
      unable to overcome by the exercise of due diligence. In the event of the
      occurrence of such a force
      majeure
      event,
      the Party unable to perform shall promptly notify the other Parties. It shall
      further use its best efforts to resume performance as quickly as possible and
      shall suspend performance only for such period of time as is necessary as a
      result of the force
      majeure
      event.

     

    ARTICLE
      13

    MISCELLANEOUS

     

    13.1. Governing
      Law.
      The
      construction, validity, performance, and effect of this CRADA shall be governed
      by and interpreted in accordance with U.S. federal law. To the extent that
      federal law does not address an issue or that state law otherwise applies to
      any
      issue in any judicial or administrative proceeding, the Parties agree that
      Maryland law shall apply. Federal law and regulations will preempt any
      conflicting or inconsistent provisions in this CRADA.

     

    13.2. Entire
      Agreement.
      This
      CRADA constitutes the entire agreement between the Parties concerning the
      subject matter of this CRADA and supersedes any prior understanding or written
      or oral agreement.

     

    13.3. Headings.
      Titles
      and headings of the articles and sections of this CRADA are for convenient
      reference only, do not form a part of this CRADA, and shall in no way affect
      its
      interpretation.

     

    13.4. Waivers.
      None of
      the provisions of this CRADA shall be considered waived by any Party unless
      such
      waiver is given in writing to the other Party. The failure of a Party to insist
      upon strict performance of any of the terms and conditions hereof, or failure
      or
      delay to exercise, any rights provided herein or by law, shall not be deemed
      a
      waiver of any rights of any Party.

     

    13.5. Severability.
      The
      illegality or invalidity of any provisions of this CRADA shall not impair,
      affect, or invalidate the other provisions of this CRADA.

     

    13.6. Amendments.
      If any
      Party desires a modification or extension to this CRADA, the Parties shall,
      upon
      reasonable notice of the proposed modification or extension by the Party
      desiring the change, confer in good faith to determine the desirability of
      such
      modification or extension. Such modification or extension shall not be effective
      until and unless a written amendment is signed by the signatories to this CRADA
      or by their representatives duly authorized to execute such
      amendment.

     

    
      
        
          	USU/AFRRI - HJF - CCF - CBL CRADA 	
                   PROPRIETARY/CONFIDENTIAL
                    INFORMATION

                

        

      

      
        
          

        

      

      
        
        

      

    

    13.7. Assignment.
      Neither
      this CRADA nor any rights or obligations of any Party hereunder shall be
      assigned or otherwise transferred by any Party without the prior written consent
      of the other Parties.

     

    13.8. Notices.
      All
      notices pertaining to or required by this CRADA shall be in writing and shall
      be
      signed by an authorized representative and shall be delivered by hand or sent
      by
      certified mail, return receipt requested, with postage prepaid, to the addresses
      indicated on the signature page for each Party. Any Party may change such
      address by notice given to the other Party in the manner set forth
      above.

     

    13.9. Independent
      Contractors.
      The
      relationship of the Parties to this CRADA is that of independent contractors
      and
      not agents of each other or joint venturers or partners. Each Party shall
      maintain sole and exclusive control over its personnel and operations. [
      employees who will be working at USU facilities may be asked to sign a Guest
      Researcher or Special Volunteer Agreement appropriately modified in view of
      the
      terms of this CRADA.]

     

    13.10. Use
      of Name or Endorsements.
      The
      Collaborators shall not use the name of USU or the Foundation in any
      advertising, press release, or promotional or sales literature, without their
      prior written consent. By entering into this CRADA, USU and the Foundation
      do
      not directly or indirectly endorse any product or service provided, or to be
      provided, whether directly or indirectly related either to this CRADA or to
      any
      patent or other IP license or agreement that implements this CRADA, by the
      Collaborators, their successors, assignees, or licensees. The Collaborators
      shall not in any way state or imply that this CRADA is an endorsement of any
      such product or service by the Government or any of its organizational units
      or
      employees. Collaborator-issued press releases that reference or rely upon the
      work of USU or the Foundation under this CRADA shall be made available to USU
      and the Foundation at least ten- (10) business days prior to publication for
      review and comment.

     

    ARTICLE
      14

    DURATION
      OF AGREEMENT

     

    14.1. Duration.
      This
      CRADA expires five- (5) years after its Effective Date, unless otherwise
      extended in writing according to the provisions of Section 13.6. It is mutually
      recognized that the duration of this project cannot be rigidly defined in
      advance and that the contemplated time periods for various phases of the RP
      are
      only good faith guidelines subject to adjustment by mutual agreement to fit
      circumstances as the RP proceeds.

     

    14.2. Survival.
      The
      provisions of Articles 2, 5 through 8 inclusive, and 12, as well as Sections
      4.2, 10.3, 10.4, 11.1, 13.1 through 13.5 inclusive, 13.7 through 13.10
      inclusive, and 14.2, shall survive the termination or expiration of this
      CRADA.

     

     

    

    REMAINDER
      OF PAGE INTENTIONALLY LEFT BLANK

    

    SIGNATURE
      PAGE TO FOLLOW

     

     

     

    
      
        
          	USU/AFRRI - HJF - CCF - CBL CRADA 	
                   PROPRIETARY/CONFIDENTIAL
                    INFORMATION

                

        

      

      
        
          

        

      

      
        
        

      

    

     

    
    

    Signature
      page for CRADA between USU, Foundation and Collaborator:

     

    FOR
      USU:

     

    
      	/s/ James A. Zimble, M.D.	 	Date: September 10, 2004
	
              James
                A. Zimble, M.D.

              President

            	 	 
	
            	 	 
	 	 	 
	
              Mailing Address for Notices:

               

            	 	 
	
              Uniformed
                Services University of the Health Sciences

              ATTN:
                General Counsel

              4301
                Jones Bridge Road

              Bethesda,
                MD 20814

            	 
	 	 	 
	 	 	 
	FOR THE
              FOUNDATION:	 	 
	 	 	 
	
              /s/
                John W. Lowe

            	 	Date: August 18, 2004
	
              John
                W. Lowe

              President

            	 	
            
	 	 	
            
	Mailing Address for Notices:	 	
            
	
            	 	
            
	
              The
                Henry M. Jackson Foundation for the Advancement of Military Medicine,
                Inc.

              ATTN:
                General Counsel

              1401
                Rockville Pike

              Suite
                600

              Rockville,
                MD 20852

            	
            
	 	 	
            
	 	 	
            
	FOR COLLABORATOR
              CCF:	 	
            
	 	 	
            
	/s/ Paul E. DiCorleto, Ph.D.	 	Date: September 15, 2004
	
              Paul
                E. DiCorleto, Ph.D.

              Chairman
                of the Lerner Research Institute

            	 	 
	 	 	 
	 	 	 
	Mailing Address for Notices of a Scientific
              Nature:	 	 
	 	 	 
	
              Andrei
                Gudkov, Ph.D.

              The
                Cleveland Clinic Foundation

              Lerner
                Research Institute / Mailcode NC2O

              9500
                Euclid Avenue

              Cleveland,
                OH 44195

            	 	 

    

     

    
      
        
          	USU/AFRRI - HJF - CCF - CBL CRADA 	
                   PROPRIETARY/CONFIDENTIAL
                    INFORMATION

                

        

        
          
            

          

        

      

    

     

    
      	 	 	 
	Mailing Address for other Notices:	 	 
	 	 	 
	
              Commercialization
                Counsel

              CCF
                Innovations/Mailcode ND2O

              9500
                Euclid Avenue

              Cleveland,
                OH 44195

            	 	 
	 	 	 
	 	 	 
	FOR COLLABORATOR
              CBL:	 	 
	 	 	 
	/s/ Michael Fonstein, Ph.D.	 	Date: September
              21, 2004
	
              Michael
                Fonstein, Ph.D.

              Chief
                Executive Officer

            	 	 
	
            	 	 
	Mailing Address for Notices:	 	 
	 	 	 
	
              Cleveland
                BioLabs, Inc.

              10265
                Carnegie Avenue

              Cleveland,
                OH 44106

              Attn:
                Michael Fonstein, Ph.D.

            	 	 
	 	 	 
	 	 	 
	ACKNOWLEDGED:	 	 
	 	 	 
	/s/
              COL David G. Jarrett, MC, USA  	 	 Date:
              August 18, 2004
	
              COL
                David G. Jarrett, MC, USA

              Director

              USU/AFRRI

            	 	 
	 	 	 
	 	 	 
	/s/ Mark H. Whitnall, Ph.D.	 	Date: August
              18, 2004
	
              Mark
                H. Whitnall, Ph.D.

              USU/AFRRI
                Principal Investigator

              Team
                Leader

              USU/AFRRI
                Radiation Casualty Management Team

            	 	 
	 	 	 

    

     

    
      	USU/AFRRI - HJF - CCF - CBL CRADA 	
               PROPRIETARY/CONFIDENTIAL
                INFORMATION

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}]]